title: Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria.
abstract: OBJECTIVE
  It is established that cirrhotic patients who respond to beta-blockers by lowering their hepatic venous pressure gradient (HVPG) to < or =12 mmHg or by > or =20% of the baseline values are protected from bleeding. However, it is not known whether the effect remains unchanged over the treatment period.
  
  
  METHODS
  A group of 24 patients with cirrhosis and oesophageal varices, treated with beta-blockers+/-nitrates, good-responders on haemodynamic criteria, were followed for up to 76 months with sequential HVPG measurements. Another group of 16 patients was used for validation.
  
  
  RESULTS
  HVPG worsened in 10 of the 24 patients during follow-up. Changes in HVPG correlated to concomitant changes in liver function parameters. Variceal bleeding occurred in four of the 10 patients whose HVPG had worsened (bleed; 3-21 months after the measured increase in HVPG) and in none of those with stable HVPG (p=0.02). Patients with increased HVPG also had shorter survival (p=0.05). Worsening of HVPG was an independent predictor of death, additive to Child-Pugh or MELD scores, in a time-dependent Cox's regression analysis. This relationship was confirmed in the validation group.
  
  
  CONCLUSIONS
  Worsening HVPG during follow-up in patients who had initially been good-responders to medical treatment is related to worsening in hepatic function. The maintenance of a good haemodynamic response to medical treatment of portal hypertension is an excellent predictor of outcome in these patients.
authors.affiliation: Department of Clinical and Experimental Medicine, University of Padua, Italy. carlo.merkel@unipd.it
authors.forename: Carlo
authors.initials: C
authors.lastname: Merkel
authors.forename: Massimo
authors.initials: M
authors.lastname: Bolognesi
authors.forename: Annalisa
authors.initials: A
authors.lastname: Berzigotti
authors.forename: Piero
authors.initials: P
authors.lastname: Amodio
authors.forename: Lucia
authors.initials: L
authors.lastname: Cavasin
authors.forename: Ilaria Maria
authors.initials: IM
authors.lastname: Casarotto
authors.forename: Marco
authors.initials: M
authors.lastname: Zoli
authors.forename: Angelo
authors.initials: A
authors.lastname: Gatta
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D018450:Disease Progression; D004932:Esophageal and Gastric Varices / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D006975:Hypertension, Portal / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology*; D008099:Liver / Q000503:physiopathology; D008103:Liver Cirrhosis / Q000175:diagnosis / Q000503:physiopathology*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D012044:Regression Analysis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists